
|Videos|June 9, 2020
SARS-CoV-2 Vaccine: Does Nucleocapsid DNA Lead to Lasting Protection?
Author(s)Grant M. Gallagher
Patrick Soon-Shiong, MD, explains why an ImmunityBio SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.
Advertisement
Segment Description: Patrick Soon-Shiong, MD, Chairman & CEO of ImmunityBio, explains why the firm's SARS-CoV-2 vaccine candidate uses Nucleocapsid DNA alongside Spike DNA.
Advertisement
Advertisement
Advertisement
Trending on Contagion Live
1
Wastewater Surveillance’s Role in Identifying Measles Outbreaks
2
ASM Microbe Conference: Bringing the Microbiology Community Together
3
Aging With HIV: Managing Comorbidities in a Population That Has Outlived Its Prognosis
4
Flu Vaccine Efficacy in Children Demonstrated in "Natural" Randomized Trial
5





































































































































































